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Summary
Background: Mutations in the cardiac myosin-binding protein C gene (MYBPC3) have been
reported to be associated with delayed expression of hypertrophic cardiomyopathy (HCM) and
a relatively good prognosis.
Purpose: The aim of this study was to evaluate clinical manifestations in patients with familial
HCM caused by a novel nonsense mutation, S297X, in MYBPC3.
Methods: We analyzed the sarcomere protein genes in 93 probands with HCM.
Results: The nonsense mutation S297X in MYBPC3 was present in nine subjects from two
unrelated families. Eight of those nine subjects with this mutation were found to be phenotype-
positive and the remaining individual was not affected phenotypically. The age range at
diagnosis was 9—75 years. There was no family history of sudden death in either family. At
presentation, there were various left ventricular hypertrophy (LVH) patterns, including Maron
type III hypertrophy from the LV base to apex, hypertrophy conﬁned to the anterolateral wall at
the basal LV wall. Two patients showed a signiﬁcant LV outﬂow tract gradient and one patient
showed intra-right-ventricular obstruction. During follow-up, one patient was repeatedly hos-
pitalized for the treatment of heart failure after development of paroxysmal atrial ﬁbrillation
at the age of 86 years and the remaining eight subjects were in relatively stable condition and
did not require hospitalization for the treatment of HCM-related events.
Conclusion: The novel mutation S297X in MYBPC3 causes HCM in a broad range of ages and
heterogeneous clinical manifestations, though the clinical course in patients with this mutation
seems to be benign.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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ypertrophic cardiomyopathy (HCM) is a primary myocardial
isorder, clinically deﬁned as thickening of the myocardial
all in the absence of any other cause for left ventricu-
ar hypertrophy (LVH) [1—4]. Molecular genetic studies have
evealed that HCM is caused by mutations in more than 10
enes that encode sarcomere contractile proteins [5—7].
esults of preliminary genetic studies on HCM have sug-
ested that particular gene abnormalities were related to
peciﬁc clinical phenotypes such as degree of hypertrophy,
isk of sudden death, onset time of the disease, and pen-
trance in families. For example, patients with -myosin
eavy chain gene (MYH7) mutations tend to have severe dis-
ase of early onset [8,9]. Cardiac troponin T gene (TNNT2)
utations are generally associated with a high incidence of
udden death despite only mild LVH [10,11]. On the other
and, mutations in the cardiac myosin-binding protein C
ene (MYBPC3) have been reported to be associated with
elayed expression of hypertrophy and a relatively good
rognosis [12—16].
The purpose of this study was to evaluate clinical man-
festations in patients with familial HCM caused by a novel
onsense mutation, S297X, in MYBPC3.
ethods
ubjects
he subjects were 93 probands with familial or sporadic
CM who were seen at Kochi Medical School Hospital. The
iagnosis of HCM was based on echocardiographic demon-
tration of an unexplained LVH, i.e., maximum LV wall
hickness≥ 15mm. Following identiﬁcation of the S297X
utation in MYBPC3, pedigree analysis, including both clin-
cal evaluation and genotyping, was performed. Informed
onsent was obtained from all subjects or their parents in
ccordance with the guidelines of the Ethics Committee on
edical Research of Kochi Medical School.
linical evaluations
valuation of probands and relatives included medical
istory, clinical examination, 12-lead electrocardiography
ECG), M-mode, two-dimensional (2D) and Doppler echocar-
iography, and ambulatory 24-h Holter ECG analysis. The
everity and distribution of LVH were assessed in the
arasternal short axis plane at mitral valve and papil-
iary muscle levels [17,18]. Maximum LV wall thickness was
eﬁned as the greatest thickness in any single segment.
eft ventricular end-diastolic diameter (LVEDD) and end-
ystolic diameter (LVESD) were measured from M-mode and
D images obtained from parasternal long-axis views, and
ractional shortening (FS = 100× ((LVEDD− LVESD)/LVEDD))
as calculated. LV outﬂow tract gradient was calculated
rom continuous-wave Doppler using the simpliﬁed Bernoulli
quation. Right ventricular wall thickness was evaluated in
he parasternal long-axis view, and a wall thickness of more
han 5mm was deﬁned as hypertrophy.
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Phenotype-positive was deﬁned by the following crite-
ia for relatives: (1) maximum LV wall thickness≥ 13mm;
2) presence of major abnormalities on ECG (i.e., Q
ave≥ 0.04 s in duration or one-fourth of the ensuing R wave
n depth in at least two leads, signiﬁcant ST-T changes, and
omhilt-Estes score > 4); or (3) a combination of criteria 1
nd 2.
Data regarding survival and clinical status of patients
ere collected during serial clinic visits. Evaluation of the
henotype was completed before the determination of the
enotype.
enetic analysis
eripheral blood samples were taken at the time of clini-
al evaluation, and they were frozen and stored at −20 ◦C.
eoxyribonucleic acid (DNA) was extracted using a DNA
uriﬁcation kit from QIAGEN Inc. (no. 51104; Hilden, Ger-
any). In vitro ampliﬁcation of genomic DNA was performed
sing the polymerase chain reaction (PCR). Information
n primer sequences and PCR conditions is available upon
equest. Sequencing was performed using a BigDye Termi-
ator Cycle Sequencing Kit from Applied Biosystems Inc.
no. 4336774; Foster City, CA, USA). The sequences were
nalyzed on an ABI PRISM 3100-Avant Genetic Analyzer in
ccordance with the manual of the manufacturer. In patients
n whom the mutation was identiﬁed, conﬁrmation was
btained by re-analysis with direct sequencing from a sec-
nd blood sample. Mutation analysis was carried out for
he 5 most common sarcomere protein gene abnormali-
ies: MYBPC3, MYH7, TNNT2, cardiac troponin I (TNNI3), and
lpha-tropomyosin (TPM1) genes.
esults
enetic results
ourteen mutations were identiﬁed in 28 probands: S297X,
106fs, H379P, V593fs, G805S, R945fs in MYBPC3, R243C,
562K, R663C, R869C, E1049D, T1928M in MYH7, D46 V in
NNT2, and R162W in TNNI3 [19,20]. The nonsense mutation
297X in MYBPC3 (a C-to-G transition in exon 9 replacing a
erine residue with a termination signal) was identiﬁed in
wo of the 93 HCM probands. Relatives of two probands,
otaling 11 members, were studied further. Genetic anal-
sis revealed that a total of nine subjects, including two
robands, had an S297X mutation (Fig. 1). This mutation
as thought to be disease-causing based on presence of the
utation in all affected individuals and absence of sequence
ariation in at least 200 chromosomes from healthy individ-
als.
linical manifestations
he clinical characteristics of the nine subjects at presenta-
ion are summarized in Table 1. Eight of those nine patients
ith an S297X mutation were found to be phenotype-
ositive: seven patients with echocardiographic evidence
f increased LV wall thickness and one patient (H087-III-
) with only ECG abnormality (maximum LV wall thickness
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mFigure 1 Pedigree of families H083 and H087. The geno
of 11mm). The remaining individual (H083-IV-3) was not
affected phenotypically (age at last evaluation: 12 years). Of
the eight phenotype-positive patients, three patients were
evaluated because of symptoms, one patient because of ECG
abnormality, and four patients because of family screening.
The age range at diagnosis was 9—75 years. One patient
(H083-IV-1) showed deﬁnite LV hypertrophy on echocardio-
graphy (maximum LV wall thickness: 19mm) without any
symptoms at 9 years of age. None of those patients showed
ventricular tachycardia. There was no family history of
sudden death in either family. Table 2 shows the echocar-
diographic characteristics of the nine subjects with this
mutation at initial evaluation. At presentation, there were
various LVH patterns, although many patients showed Maron
type III hypertrophy. Two patients showed a signiﬁcant LV
outﬂow tract gradient (pressure gradient at rest≥ 30 mmHg)
and one patient showed intra-right-ventricular obstruction
(gradient: 13mmHg). Right ventricular hypertrophy was
seen in three patients.Table 3 shows the clinical courses of the nine subjects
with this mutation. One patient (H087-II-6) was repeatedly
hospitalized for the treatment of heart failure after a devel-
opment of paroxysmal atrial ﬁbrillation, although LV systolic
function was preserved at the last follow-up (Fig. 2). She had
S
p
s
rstatus and phenotypic status of subjects are indicated.
ormal coronary angiography. The remaining eight subjects
ere in relatively stable condition and did not require hos-
italization for the treatment of HCM-related events. One
atient (H083-IV-1), who was diagnosed as having HCM at 9
ears of age, had progression of increased LV wall thickness
19—25mm over a period of 3 years).
iscussion
his is a ﬁrst report on detailed clinical presentations of
atients with a novel mutation, S297X, in MYBPC3 [19]. The
esults in this study provide an additional insight into the
linical manifestations of MYBPC3 gene abnormalities.
To date, more than 200 different mutations in differ-
nt sarcomere genes have been reported in patients with
CM [5—7]. Nonsense mutations were found much less fre-
uently than missense mutations in sarcomere genes, and
ost of them were reported to be in MYBPC3 [21,22]. An
297X mutation is thought to result in a truncation of the
rotein, including loss of C-terminal myosin and titin binding
ites [5,23].
This novel nonsense mutation causes HCM in a broad
ange of ages. One patient (H083-IV-1) was diagnosed as
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Figure 2 Images of transthoracic echocardiography. (a) 2D echocardiography (diastole) showing increased interventricular septal
thickness of 19mm and pericardial effusion. (b) 2D echocardiography (systole). (c) M-mode echocardiography showing normal systolic
function. IVS, interventricular septum thickness; PW, posterior wall thickness; LVEDD, left ventricular end-diastolic diameter; FS,
fractional shortening; LAD, left atrial diameter.
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Table 1 Clinical characteristics of patients with an S297X mutation in MYBPC3 at initial evaluation.
Patient no. Gender Age (years) at initial Age (years) at diagnosis Reason for diagnosis NYHA class Rhythm Abnormal Q ST-T change
H083-II-2 F 61 57 Symptom (chest pain) I Sinus rhythm + +
H083-III-2 F 40 38 Symptom (dyspnea) II Sinus rhythm + +
H083-III-4 F 39 35 ECG abnormality I Sinus rhythm − +
H083-IV-1 F 9 9 Family screening I Sinus rhythm − +
H083-IV-3 M 10 (10) Family screening I Sinus rhythm − −
H087-II-6 F 75 75 Symptom (dyspnea) II Sinus rhythm − +
H087-III-2 F 58 58 Family screening I Sinus rhythm − +
H087-IV-1 M 36 36 Family screening I Sinus rhythm − +
H087-IV-3 M 32 32 Family screening I Sinus rhythm − −
MYBPC3, cardiac myosin-binding protein C gene; NYHA, New York Heart Association functional class; F, female; M, male; ECG, electrocardiography.
Table 2 Echocardiographic characteristics of patients with an S297X mutation in MYBPC3 at initial evaluation.
Patient No. IVS (mm) PW (mm) MLVWT (mm) LVEDD (mm) FS (%) LAD (mm) LVOTO RVO RVH LVH pattern
H083-II-2 16 9 18 37 41 38 − − + Maron III (base-apex)
H083-III-2 12 9 18 39 49 37 − + − Maron III (mid-apex)
H083-III-4 21 9 26 38 51 39 + − + Maron III (base-apex)
H083-IV-1 12 6 19 33 54 29 − − − Concentric (mid-apex)
H083-IV-3 6 6 9 34 38 25 − − − No LVH
H087-II-6 21 10 22 40 40 51 + − + Maron III (base-apex)
H087-III-2 10 10 11 41 46 38 − − − No LVH
H087-IV-1 9 9 16 54 42 43 − − − Inferoseptum (mid-apex)
H087-IV-3 12 11 15 46 46 41 − − − Anterolateral (base)
MYBPC3, cardiac myosin-binding protein C gene; IVS, interventricular septum thickness; PW, posterior wall thickness; LVEDD, left ventricular end-diastolic diameter; FS, fractional
shortening; LAD, left atrial diameter; LVOTO, left ventricular outﬂow tract obstruction; RVO, intra-right-ventricular obstruction; RVH, right ventricular hypertrophy; LVH, left ventricular
hypertrophy.
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Table 3 Clinical course of patients with an S297X mutation in MYBPC3 during follow-up.
Patient no. Gender Age (years)
at initial
Rhythm change NYHA change Hospitalization for heart
failure, age (years)
Status, age
(years)
H083-II-2 F 61 SR→ SR I→ I − Alive (stable),
66
H083-III-2 F 40 SR→ SR II→ II − Alive (stable),
45
H083-III-4 F 39 SR→ SR I→ I − Alive (stable),
43
H083-IV-1 F 9 SR→ SR I→ I − Alive
(developing
LVH;
19→ 25mm),
13
H083-IV-3 M 10 SR→ SR I→ I − Alive (no LVH),
12
H087-II-6 F 75 SR→PAF II→ III +, 86 Alive, 88
H087-III-2 F 58 SR→ SR I→ I − Alive (no LVH
on echocardio-
graphy),
60
H087-IV-1 M 36 SR→ SR I→ I − Alive (stable),
37
H087-IV-3 M 32 SR→ SR I→ I − Alive (stable),
33
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ReferencesMYBPC3, cardiac myosin-binding protein C gene; NYHA, New York H
PAF, paroxysmal atrial ﬁbrillation; LVH, left ventricular hypertrop
aving the disease at 9 years of age. On the other hand,
nother patient (H087-II-6) was diagnosed at the age of 75
ears, although it was unknown when the patient actually
eveloped hypertrophy. Although previous studies showed
hat mutations in MYBPC3 were associated with delayed
xpression of hypertrophy, the present study indicates that
arly onset of HCM can be frequently seen in subjects with
MYBPC3 mutation [12—16].
The distribution of hypertrophy was various, and maxi-
um LV wall thickness ranged from 9 to 26mm. From the
oint of hemodynamic ﬁndings, there were different sub-
ypes of HCM: two patients had LV outﬂow tract obstruction
nd one patient showed intra-right-ventricular obstruction.
he fact that patients with identical mutations showed
eterogeneous clinical presentations suggests that other
enetic and/or environmental factors are involved.
In the present study, the clinical course of this mutation
eemed to be benign, although one patient was repeat-
dly hospitalized for the treatment of heart failure after
he onset of atrial ﬁbrillation at the age of 86 years. It is
uggested that younger patients with this mutation must be
ollowed carefully for a long period. We recently reported
hat a different truncation mutation in MYBPC3 (V593fs:
e altered the name V592fs/8) was associated with ‘end-
tage’ HCM characterized by LV systolic dysfunction, cavity
ilatation, and irreversible heart failure and speculated that
collapse of sarcomere stability compensated by residual
rotein in heterozygous patients might occur with advanc-
ng age and might lead to impaired contractile function
n the elderly [20,24]. However, patients with S297X trun-
ation mutation, even elderly patients, did not show LVAssociation functional class; F, female; M, male; SR, sinus rhythm;
ystolic dysfunction, although the number of the patients
ith this mutation was small. On the other hand, Konno et
l. reported that a missense mutation (R820Q) in MYBPC3
s responsible for HCM with LV systolic dysfunction and
ilatation [25]. Although truncation mutations are gener-
lly thought to cause greater alterations of protein structure
nd function than missense mutations do, these results indi-
ate that truncation mutations do not always cause a more
evere phenotype of the disease than do missense muta-
ions from the clinical point of view. The exact biophysical
roperties altered by these abnormalities remain unknown.
urther investigations of genotype—phenotype correlations
re needed to clarify the pathogenesis of LV remodeling in
CM.
In conclusion, a novel mutation, S297X, in MYBPC3 was
dentiﬁed in two of 93 probands with HCM. This nonsense
utation causes HCM in a broad range of ages and hetero-
eneous clinical manifestations, although the clinical course
n patients with this mutation seems to be benign.
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